Why the study?
Do ACE inhibitors improve quality of life in patients with chronic heart failure compared to placebo or other vasodilators?
Do ACE inhibitors improve quality of life in patients with chronic heart failure compared to placebo or other vasodilators?
This review suggests that ACE inhibitors provide small, sometimes nonsignificant improvements in quality of life for patients with chronic heart failure.
Answers are grounded in this paper and cite their sources.
Small, inconsistent QoL benefits with ACE inhibitors in chronic HF; leaves open their role versus other vasodilators.
The randomized trials assessing the effect of angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure (CHF) are reviewed. The Minnesota Living with Heart Failure Questionnaire has demonstrated the benefits of enalapril in some but not all circumstances and the Yale Dyspnea-Fatigue Index improves with lisinopril. A recent trial of both cilazapril and captopril vs. placebo employed the Sickness Impact Profile and supports the concept that ACE inhibitors have a small (and in this trial nonsignificant) beneficial effect on mobility. Other vasodilators and inotropes may also have small benefits on quality of life, such that comparisons of an ACE inhibitor with vasodilators, as was done in the V-HeFT II trial, fail to reveal any different effects on quality of life.
No takes yet. Share an insight, caveat, or question.
Christopher J. Bulpitt (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: